An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ODYSSEY KIDS
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 08 Mar 2017 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
- 13 Sep 2016 Status changed from not yet recruiting to recruiting.